ChatGPT combined with big data analysis to analyze the research hotspots of engineered cells and stem cells in China

引言（来源于ChatGPT）

The research of engineered cells and stem cells is an important frontier in the field of modern biomedicine, involving regenerative medicine, tissue engineering, cancer treatment and other aspects. Here are some of the current research hotspots and future directions:

Research hotspots

1. Cell Reprogramming Technology:- Application and optimization of induced pluripotent stem cells (iPSCs) technology to explore how to efficiently generate pluripotent stem cells from adult cells.
2. Gene Editing Technology:- The development and application of gene editing tools such as CRISPR/Cas9 to promote the functional research of stem cells and the treatment of genetic diseases.
3. Tissue engineering:- Construct 3D tissues or organs using engineered cells, especially in organ transplantation and regenerative medicine.
4. Stem cell differentiation mechanism:- To study the mechanism of stem cell differentiation to specific cell types to improve therapeutic efficacy and safety of cell therapy.
5. Interaction of stem cells with the immune system:- To explore the role of stem cells in immune regulation, especially in the potential applications of autoimmune diseases and inflammatory responses.
6. Synthetic Biology:- Applying synthetic biology methods, design and construct engineered cells with specific functions for drug delivery and disease models.

Future directions

1. Personalized Medicine:- Combine the patient's genomic information to develop a personalized stem cell treatment plan to improve efficacy and reduce side effects.
2. Clinical Application and Translational Research:- Strengthen the translation of basic research into clinical application, and promote the clinical trial and practical application of stem cell therapy.
3. Smart Cells:- Develop "smart" engineered cells that can respond to specific signals or changes in the environment for more precise treatments.
4. Biomaterial and cell binding:- Investigate the combination of novel biomaterials with stem cells to improve cell survival and function after cell transplantation.
5. Ethical & Regulatory Issues:- As stem cell research progresses, the relevant ethical and legal frameworks need to be continuously improved to ensure the safety and compliance of the research.
6. Interdisciplinary Collaboration:- Promote the integration of biology, engineering, computer science and other disciplines to promote innovation in engineered cell and stem cell research.

Research on engineered cells and stem cells is advancing at a rapid pace, and future development depends not only on technological advances, but also on ethical, legal, and social considerations. Through multidisciplinary collaboration and clinical translation, we are expected to achieve greater breakthroughs in the field of regenerative medicine and cell therapy.

Big data analytics

检索数据库：Medline

检索工具：文献鸟/PubMed

Search time: 2024-09-07

检索词：(stem cells or stem cell) AND China [ad]

1. Overview of the paper

In recent years, China has published 96,118 research articles related to engineered cells and stem cells indexed by Medline, and we conducted big data analysis on 9,996 articles included in it, including 2,135 articles published in 2023 and 7,838 articles newly published in 2024. Use ChatGPT to learn more about the research hotspots of engineered cells and stem cells.

2. Engineered cell and stem cell research institutions active in China: Sichuan University published 255 papers, Zhejiang University (181 papers), Central South University (176 papers), Southern Medical University (167 papers), Tongji University (140 papers), Capital Medical University (140 papers), Shanghai Jiao Tong University School of Medicine (125 papers), Huazhong University of Science and Technology (117 papers), Peking University People's Hospital (112 papers), Fudan University (110 papers), etc.

Hospitals with active publications on engineered cell and stem cell research in China: West China Hospital published 126 papers, Peking University People's Hospital (115 papers), The First Affiliated Hospital of Zhejiang University (89 papers), The First Affiliated Hospital of Soochow University (88 papers), Institute of Hematology and Blood Disease Hospital (77 papers), West China Stomatological Hospital (76 papers), Union Hospital Affiliated to Tongji Medical College (75 papers), Xiangya Hospital (69 papers), etc.

3. Journals published by Chinese authors of engineered cell and stem cell research:

从发文来看，发表来自中国工程化细胞及干细胞研究文章数量较多的期刊有Stem Cell Res Ther (IF: 7.1)、Nat Commun (IF: 14.7)、Heliyon (IF: 3.4)、Front Immunol (IF: 5.7)、Adv Sci (Weinh) (IF: 15.8)、Stem Cell Res (IF: 0.8)、Int J Mol Sci (IF: 4.9)、J Nanobiotechnology (IF: 10.6)等。

4. Engineered cell and stem cell research: active scholars and their networks in China

Active experts in engineered cell and stem cell research in China: Hu, Yongxian, Zhejiang University School of Medicine; Huang, He, Zhejiang University; Li, Wei, Chinese Academy of Sciences; Liu, Guanghui, Chinese Academy of Medical Sciences; Xu, Ren, Xiamen University; Zhang, Bing et al. from Shanghai Jiao Tong University are active in this research field. There are many more excellent researchers, and it is impossible to list them all due to space limitations.

Limitations of this data analysis:

A. This report is a visual report based on the PubMed database based on the PubMed database, based on the search results of the set search terms, within a limited time and number of documents.

B. The purpose of the big data analysis of the "Literaturebird" analysis tool is to present an overview of recent research in the field and is for academic communication purposes only; There is no ranking significance.

C. The statistical ranking of the results of the "Literature Bird" analysis tool on the active unit, author, etc., and only the number of papers in the unit where the first author's paper is located is counted; That is, after the paper is retrieved and downloaded, only the first author's unit is retained for each paper, and then the number of papers in each unit is counted. When there are different spellings of the same unit, PubMed treats it as two different units. In the same authorship arrangement, only the number of papers published by the first author and the last author is counted. If the author's name has a different spelling, it will be processed by the PubMed search platform according to the different authors.

D. The conclusion of this paper is completely from the "Literature Bird" analysis tool, due to the limitations of search terms, the scope of literature included in the search database and the search time, it does not represent the views of this journal, and the data content is likely to be inaccurate.